Acute Respiratory Distress Syndrome Mimics

Introduction to ARDS Mimics

• The European Respiratory Society notes that ARDS-mimics are conditions presenting with similar clinical features to ARDS but requiring distinct treatments such as immunosuppressants, antimicrobials, or drug withdrawal, making their recognition essential to prevent inappropriate management and improve outcomes 1, 2

Key Categories of ARDS Mimics

• The European Respiratory Society recommends considering diffuse interstitial acute lung diseases, such as acute interstitial pneumonia, which presents with bilateral infiltrates and hypoxemia and may respond to corticosteroids 1, 2
• Organizing pneumonia can mimic ARDS radiographically but typically requires immunosuppressive therapy 2
• Acute eosinophilic pneumonia responds dramatically to corticosteroids, unlike typical ARDS 1
• Hypersensitivity pneumonitis requires identification and removal of the inciting antigen 2

Diffuse Pulmonary Infections

• Pneumocystis jirovecii pneumonia requires trimethoprim-sulfamethoxazole and adjunctive corticosteroids 1, 3
• Viral pneumonitis, including COVID-19 and influenza, may benefit from antiviral therapy and targeted corticosteroid use 2, 4
• Disseminated fungal infections require antifungal therapy 1
• Miliary tuberculosis demands anti-tuberculous therapy 2

Drug/Chemical-Induced Diffuse Lung Disease

• Vaping-induced lung injury exemplifies how ARDS-mimics can emerge rapidly and require specific recognition 1, 2
• Chemotherapy-induced pneumonitis may require corticosteroids and drug discontinuation 1
• Amiodarone toxicity requires drug withdrawal and possible corticosteroid therapy 2
• Drug-induced acute interstitial pneumonitis resolves with drug cessation 4

Critical Diagnostic Approach

• The European Respiratory Society recommends establishing and applying a diagnostic protocol to identify treatable diseases within the syndrome diagnosis of ARDS, including obtaining detailed exposure history, assessing immune status, considering bronchoscopy with bronchoalveolar lavage, evaluating for systemic disease, and reviewing temporal relationship 1, 2

Management Implications

• Withdraw offending agents immediately in drug/chemical-induced disease 1, 2
• Initiate pathogen-specific antimicrobial therapy for infectious mimics 1, 4
• Consider immunosuppression, particularly corticosteroids, for inflammatory/autoimmune mimics 1, 2
• Continue lung-protective ventilation as supportive care while treating the underlying condition 1, 2

Special Considerations

• COVID-19 ARDS benefits from dexamethasone, unlike typical ARDS where routine corticosteroids are not recommended 2
• Influenza-associated ARDS with hemorrhage requires immediate oseltamivir regardless of symptom duration in severe disease 2

ARDS Mimics Recognition and Management

Introduction to ARDS Mimics

• The European Respiratory Society emphasizes that ARDS-mimics show known and distinct pathophysiology requiring specific treatment, and these patients may be inappropriately included in clinical trials if additional diagnostic tests are not performed 5
• Recognition of the underlying cause is essential because adequate treatment of the underlying disease is one of the fundamentals of ARDS care, as stated by the European Respiratory Society 6
• Only a minority of patients who fulfill current ARDS criteria actually have diffuse alveolar damage at autopsy, highlighting the heterogeneity within the syndrome 7

Diagnostic Considerations

• The European Respiratory Society recommends establishing and applying a diagnostic protocol to identify treatable diseases within the syndrome diagnosis of ARDS 6
• The American Thoracic Society notes that computerized tomographic scanning can separate pleural fluid from parenchymal disease and demonstrate parenchymal abscesses, helping distinguish focal pneumonia from diffuse ARDS 8
• In patients with severe community-acquired pneumonia, ARDS was not a risk factor for mortality, suggesting these may represent distinct entities, according to the European Respiratory Society 6

Management of ARDS Mimics

• Open lung biopsy should be considered when bronchoscopy demonstrates no unusual or resistant organisms, aggressive search for extrapulmonary infectious foci is unrevealing, and the patient deteriorates despite appropriate empiric therapy, as suggested by the American Journal of Respiratory and Critical Care Medicine 8
• The available evidence does not suggest a clear outcome benefit for open lung biopsy in nonimmunosuppressed patients, so the decision should be reserved for cases where diagnosis remains elusive despite comprehensive evaluation, according to the American Journal of Respiratory and Critical Care Medicine 8
• Iatrogenic injury from excess fluid administration, transfusions, or injurious mechanical ventilation should be considered a "second hit" that aggravates pulmonary edema in patients with ARDS risk factors, as noted by the European Respiratory Society 6

Identifying and Managing ARDS Mimics

Introduction to ARDS Mimics

• The European Respiratory Society recommends establishing a systematic diagnostic protocol to identify treatable diseases masquerading as ARDS, focusing on three key categories: diffuse interstitial acute lung diseases, diffuse pulmonary infections, and drug/chemical-induced diffuse lung disease 9, 10
• ARDS-mimics present with bilateral infiltrates and hypoxemia that meet Berlin criteria but have distinct pathophysiology requiring specific treatments, such as immunosuppressants, antimicrobials, or drug withdrawal, rather than standard ARDS supportive care 9, 10

Diagnostic Approach

• The American Thoracic Society suggests that substance use, including vaping, injection drug use, and recreational drugs, should be specifically asked about in patients with suspected ARDS-mimics 11, 12
• A detailed exposure history, including occupational and environmental exposures, medication review, travel history, and animal exposures, is crucial in identifying potential causes of ARDS-mimics 12
• Bronchoscopy with bronchoalveolar lavage has a diagnostic yield of 41% in treatment failures, identifying Legionella, anaerobes, resistant pathogens, tuberculosis, fungi, and Pneumocystis 12

Systemic Disease Evaluation

• The American College of Chest Physicians recommends evaluating for systemic disease, including connective tissue disease markers, vasculitis markers, and tuberculin skin test or interferon-gamma release assay, in patients with suspected ARDS-mimics 12

Common Pitfalls to Avoid

• Assuming all bilateral infiltrates with hypoxemia are ARDS can lead to misdiagnosis, as only a minority of patients meeting Berlin criteria actually have diffuse alveolar damage at autopsy 9
• Failing to recognize iatrogenic "second hits", such as excess fluid administration, transfusions, or injurious mechanical ventilation, can aggravate pulmonary edema in patients with ARDS risk factors 9
• Overlooking noninfectious mimics, such as pulmonary embolus, obstructing bronchogenic carcinoma, lymphoma, intrapulmonary hemorrhage, Wegener's granulomatosis, and sarcoidosis, can lead to delayed diagnosis and treatment 12